细胞培养来源的兔出血症病毒2型疫苗初步研究
本研究比较了商业疫苗与源自细胞培养病毒的实验性RHDV2疫苗。所有接种任一制剂的兔在RHDV2攻毒后均存活。初步结果提示细胞培养系统可作为RHDV疫苗生产的替代平台。
要点
- 商业疫苗与细胞培养来源实验疫苗均使兔在RHDV2攻毒后存活。
- 细胞培养系统可支持RHDV高滴度复制,为疫苗生产提供替代平台。
- 结果仅为初步,尚未描述灭活细胞培养疫苗的完整效果。
核心结论
- 细胞培养来源的RHDV2实验疫苗与商业疫苗一样,使所有接种兔在RHDV2攻毒后存活。
- RHDV培养系统有潜力成为RHDV疫苗生产的替代平台。
研究设计与样本
- 比较商业疫苗与源自细胞培养病毒的实验性RHDV2疫苗的初步研究。
- 所有接种任一制剂的兔均接受RHDV2攻毒。
主要发现
- 接种商业疫苗或实验性细胞培养来源疫苗的所有兔在RHDV2攻毒后均存活。
临床怎么用
- 细胞培养平台可能减少疫苗生产与质量保证中对兔的使用。
局限性
- 结果为初步,尚未描述灭活细胞培养来源RHDV疫苗。
- 原文未报告样本量、攻毒剂量、抗体水平等具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ongoing circulation of pathogenic rabbit haemorrhagic disease viruses (RHDV1 and RHDV2) worldwide makes vaccination of domestic rabbits essential. Most commercially available RHDV vaccines are prepared by inactivating virus purified from the tissues of infected rabbits. Although highly effective, the production of such vaccines requires the use of rabbits in both manufacturing and quality assurance, raising ethical concerns. Inactivated cell culture-derived vaccines for RHDVs have not been described, as RHDV could not be grown reliably in vitro since its discovery. A recently developed rabbit liver-derived cell culture system supports RHDV replication to high titres, providing opportunities to explore development of a cell culture-based vaccine. Here, we compared a commercially available vaccine with an experimental RHDV2 vaccine derived from culture-grown virus. All rabbits, vaccinated with either formulation, survived RHDV2 challenge. These preliminary results demonstrate the potential of the RHDV culture system as an alternative platform for RHDV vaccine production.
引用
- Smertina E, Rutherford M, Pavy M, et al. Cell culture-derived vaccine for rabbit haemorrhagic disease virus 2. Vaccine. 2026. PMID: 42617358. doi:10.1016/j.vaccine.2026.129067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。